HRP20221325T1 - Pripravci i postupci transmukozne apsorpcije - Google Patents

Pripravci i postupci transmukozne apsorpcije Download PDF

Info

Publication number
HRP20221325T1
HRP20221325T1 HRP20221325TT HRP20221325T HRP20221325T1 HR P20221325 T1 HRP20221325 T1 HR P20221325T1 HR P20221325T T HRP20221325T T HR P20221325TT HR P20221325 T HRP20221325 T HR P20221325T HR P20221325 T1 HRP20221325 T1 HR P20221325T1
Authority
HR
Croatia
Prior art keywords
preparation according
sublingual
phosphate
disease
condition
Prior art date
Application number
HRP20221325TT
Other languages
English (en)
Croatian (hr)
Inventor
Harry Brittain
Seth Lederman
Giorgio Reiner
Original Assignee
Tonix Pharma Holdings Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Holdings Limited filed Critical Tonix Pharma Holdings Limited
Publication of HRP20221325T1 publication Critical patent/HRP20221325T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
HRP20221325TT 2012-06-15 2013-06-14 Pripravci i postupci transmukozne apsorpcije HRP20221325T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261660593P 2012-06-15 2012-06-15
US201261667774P 2012-07-03 2012-07-03
US201261725402P 2012-11-12 2012-11-12
US201361792900P 2013-03-15 2013-03-15
EP13804115.7A EP2861223B1 (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption
PCT/US2013/046023 WO2013188847A1 (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption

Publications (1)

Publication Number Publication Date
HRP20221325T1 true HRP20221325T1 (hr) 2022-12-23

Family

ID=49758769

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20221325TT HRP20221325T1 (hr) 2012-06-15 2013-06-14 Pripravci i postupci transmukozne apsorpcije

Country Status (26)

Country Link
US (1) US20140171515A1 (enExample)
EP (1) EP2861223B1 (enExample)
JP (5) JP6259452B2 (enExample)
CN (2) CN111388430A (enExample)
AR (1) AR092330A1 (enExample)
AU (2) AU2013274003B2 (enExample)
BR (1) BR112014031394B1 (enExample)
CA (2) CA2876902C (enExample)
DK (1) DK2861223T3 (enExample)
ES (1) ES2929133T3 (enExample)
HR (1) HRP20221325T1 (enExample)
HU (1) HUE060175T2 (enExample)
IL (1) IL236268B (enExample)
LT (1) LT2861223T (enExample)
MX (2) MX382516B (enExample)
MY (1) MY194495A (enExample)
NZ (2) NZ631144A (enExample)
PL (1) PL2861223T3 (enExample)
PT (1) PT2861223T (enExample)
RS (1) RS63822B1 (enExample)
SG (2) SG11201408318RA (enExample)
SI (1) SI2861223T1 (enExample)
SM (1) SMT202200436T1 (enExample)
TW (3) TWI590820B (enExample)
WO (1) WO2013188847A1 (enExample)
ZA (1) ZA201500288B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062614A1 (en) 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
US9636408B2 (en) 2013-03-15 2017-05-02 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
SG10201902203VA (en) 2014-09-18 2019-04-29 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
EP3322412B1 (en) * 2015-07-15 2021-04-07 Theranexus Use of amitriptyline for blocking brain hemichannels and method for potentiating its effect in vivo
US12337063B2 (en) * 2016-09-02 2025-06-24 University Of Sharjah Formulation for atropine sulfate rapidly-disintegrating sublingual tablets
WO2019014651A1 (en) * 2017-07-13 2019-01-17 Tonix Pharmaceuticals Holding Corp. ANALOGUES OF CYCLOBENZAPRINE AND AMITRYPTILENE
CN107496355B (zh) * 2017-08-24 2021-04-30 正大制药(青岛)有限公司 一种盐酸环苯扎林舌下喷雾剂及其制备方法
CN107519142B (zh) * 2017-08-24 2021-02-26 正大制药(青岛)有限公司 一种盐酸环苯扎林舌下片及其制备方法
WO2019110723A1 (en) * 2017-12-08 2019-06-13 F. Hoffmann-La Roche Ag Pharmaceutical formulation
CA3083341C (en) 2017-12-11 2024-05-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN108721240A (zh) * 2018-06-08 2018-11-02 华益药业科技(安徽)有限公司 一种25mg阿米替林薄膜包衣片处方和工艺规程
JP7691739B2 (ja) 2018-08-20 2025-06-12 トニックス ファーマ ホールディングス リミテッド 急性ストレス障害および外傷後ストレス障害を処置する方法
CA3156118A1 (en) * 2019-09-30 2021-04-08 Cadila Healthcare Limited Intranasal pharmaceutical compositions of cyclobenzaprine
JP7780447B2 (ja) 2020-04-08 2025-12-04 トニックス ファーマシューティカルズ ホールディング コーポレイション 性機能障害のシクロベンザプリン処置
MX2023005899A (es) 2020-11-20 2023-08-16 TONIX Pharmaceuticals Holding Corp Tratamiento con ciclobenzaprina para el trastorno por consumo de alcohol.
EP4255407A1 (en) 2020-12-07 2023-10-11 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for fibromyalgia
WO2022170107A2 (en) 2021-02-04 2022-08-11 Tonix Pharmaceuticals Holding Corp. An improved method of assessing clinical response in the treatment of ptsd symptoms
US20240415789A1 (en) 2021-10-06 2024-12-19 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
US20230414536A1 (en) 2022-06-21 2023-12-28 Tonix Pharmaceuticals Holding Corp. CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-CoV-2 INFECTION (PASC)
WO2025160302A1 (en) 2024-01-25 2025-07-31 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for acute stress reaction or acute stress disorder

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) * 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
DE69904465T2 (de) * 1998-05-14 2003-10-02 Alza Corp., Mountain View Therapie von depressionen
JP2003506484A (ja) 1999-08-13 2003-02-18 ベラ・ファーマシューティカルズ・インコーポレイテッド 非常に低用量のシクロベンザプリンを使用する睡眠障害の処置または予防するための組成物使用
MXPA02001568A (es) 1999-08-13 2002-07-02 Vela Pharmaceuticals Inc Ciclobenzaprina para tratar trastornos de ansiedad generalizada y composiciones de la misma.
AU2001261744A1 (en) * 2000-05-19 2001-12-03 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2002094229A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of muscle relaxants through an inhalation route
CA2515146C (en) * 2003-02-04 2011-12-06 Chrysalis Technologies Incorporated Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
US20090117054A1 (en) * 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
JP2009079060A (ja) * 2008-10-15 2009-04-16 Novadel Pharma Inc 極性または非極性の、バッカルスプレーまたはカプセル
US20100266682A1 (en) * 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
WO2011062614A1 (en) * 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) * 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
US9636408B2 (en) * 2013-03-15 2017-05-02 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

Also Published As

Publication number Publication date
AU2018241128A1 (en) 2018-10-25
EP2861223A1 (en) 2015-04-22
WO2013188847A1 (en) 2013-12-19
IL236268B (en) 2022-03-01
RS63822B1 (sr) 2023-01-31
JP2019123757A (ja) 2019-07-25
TWI642429B (zh) 2018-12-01
MY194495A (en) 2022-11-30
PT2861223T (pt) 2022-11-07
BR112014031394B1 (pt) 2022-10-18
CA3118913C (en) 2024-04-30
MX382516B (es) 2025-03-13
NZ726488A (en) 2018-10-26
AU2018241128B2 (en) 2020-05-21
CA3118913A1 (en) 2013-12-19
JP6259452B2 (ja) 2018-01-10
EP2861223B1 (en) 2022-08-03
TWI590820B (zh) 2017-07-11
LT2861223T (lt) 2022-12-12
BR112014031394A8 (pt) 2021-11-03
SG11201408318RA (en) 2015-01-29
CA2876902A1 (en) 2013-12-19
CA2876902C (en) 2021-07-13
JP2017222726A (ja) 2017-12-21
SG10201605407TA (en) 2016-08-30
TWI683660B (zh) 2020-02-01
BR112014031394A2 (pt) 2017-06-27
HK1209361A1 (en) 2016-04-01
PL2861223T3 (pl) 2022-12-12
TW201731494A (zh) 2017-09-16
ES2929133T3 (es) 2022-11-25
HUE060175T2 (hu) 2023-02-28
TW201842903A (zh) 2018-12-16
TW201408281A (zh) 2014-03-01
CN111388430A (zh) 2020-07-10
DK2861223T3 (da) 2022-11-07
JP2024032964A (ja) 2024-03-12
MX2014015436A (es) 2015-07-14
US20140171515A1 (en) 2014-06-19
JP2021138765A (ja) 2021-09-16
ZA201500288B (en) 2022-05-25
AU2013274003A1 (en) 2015-02-05
IL236268A0 (en) 2015-02-26
SMT202200436T1 (it) 2023-01-13
AR092330A1 (es) 2015-04-15
EP2861223A4 (en) 2016-01-27
SI2861223T1 (sl) 2023-01-31
NZ631144A (en) 2016-12-23
WO2013188847A8 (en) 2015-02-05
JP2015519404A (ja) 2015-07-09
MX2021005317A (es) 2022-12-16
AU2013274003B2 (en) 2018-07-05
CN104684550A (zh) 2015-06-03

Similar Documents

Publication Publication Date Title
HRP20221325T1 (hr) Pripravci i postupci transmukozne apsorpcije
JP2015534562A5 (enExample)
JP2013231087A5 (enExample)
HRP20240231T1 (hr) Farmaceutske formulacije inhibitora brutonove tirozin kinaze
JP2015038135A5 (enExample)
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
HRP20171256T1 (hr) Farmaceutski pripravci karbetocina
HRP20180874T4 (hr) Selektivni modulatori receptora sfingozin-1-fosfata i postupci kiralne sinteze
BR112015018168A2 (pt) inibidores de rock suaves
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
EA201590933A1 (ru) Новые перорально биодоступные соединения, модулирующие контроль дыхания, и способы их использования
HRP20250972T1 (hr) Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak
JP2014218522A5 (enExample)
JP2011511793A5 (enExample)
HRP20230809T1 (hr) Liječenje alzheimerove bolesti u određenoj populaciji bolesnika
HRP20150430T1 (hr) Lijeäśenje same virusne infekcije hepatitisa b ili kombinirane s delta virusom hepatitisa te povezanih jetrenih bolesti
NZ593475A (en) Calcium salts for reducing exhalation of infectious bioaerosol particles
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
HRP20191723T1 (hr) Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
HRP20171678T1 (hr) Postupci za smanjenje prejedanja ili kompulzivnog jedenja
ME02610B (me) Aklidinijum za upotrebu u poboljšanju kvaliteta sna kod respiratornih pacijenata
HRP20192227T1 (hr) Dvojna uporaba oralnog farmaceutskog pripravka tableta sulfatnih soli i metode njihove uporabe
HRP20221344T1 (hr) Novi pripravak acetaminofenskog spoja bez nuspojave po jetru
HRP20191710T1 (hr) Postupci za liječenje poremećaja ciklusa uree